Post Hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: Associated pruritus from phase 1 and 2 clinical studies

Journal of Drugs in Dermatology

Volumn 15, Issue 2, 2016, Pages 172-176

  Draelos, Zoe Diana ^a   Stein Gold, Linda F ^b   Murrell, Dedee F ^c   Hughes, Matilda H ^d   Zane, Lee T ^d  

^a DERMATOLOGY CONSULTING SERVICES   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRISABOROLE; BORON DERIVATIVE; FUSED HETEROCYCLIC RINGS; OINTMENT;

ADOLESCENT; ADULT; AGED; APPLICATION SITE BURNING; APPLICATION SITE EROSION; APPLICATION SITE PAIN; APPLICATION SITE PAPULE; APPLICATION SITE PARESTHESIA; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE REACTION; APPLICATION SITE URTICARIA; ARTICLE; ATOPIC DERMATITIS; CHILD; DISEASE SEVERITY; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OINTMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRURITUS; RATING SCALE; RISK BENEFIT ANALYSIS; CHEMISTRY; CUTANEOUS DRUG ADMINISTRATION; DERMATITIS, ATOPIC; DRUG FORMULATION; META ANALYSIS; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; BORON COMPOUNDS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DERMATITIS, ATOPIC; DRUG COMPOUNDING; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PRURITUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84989223866     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-1494.
2. Saeki H, Furue M, Furukawa F, et al. Guidelines for management of atopic dermatitis. J Dermatol. 2009;36(10):563-577.
3. Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol. 2009;26(1):14-22.
4. Gelmetti C, Boralevi F, Seite S, et al. Quality of life of parents living with a child suffering from atopic dermatitis before and after a 3-month treatment with an emollient. Pediatr Dermatol. 2012;29(6):714-718.
5. Al Shobaili HA. The impact of childhood atopic dermatitis on the patients’ family. Pediatr Dermatol. 2010;27(6):618-623.
6. Camfferman D, Kennedy JD, Gold M, Martin AJ, Lushington K. Eczema and sleep and its relationship to daytime functioning in children. Sleep Med Rev. 2010;14(6):359-369.
7. Camfferman D, Kennedy JD, Gold M, Simpson C, Lushington K. Sleep and neurocognitive functioning in children with eczema. Int J Psychophysiol. 2013;89(2):265-272.
8. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.
9. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15.
10. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349.
11. Freund YR, Akama T, Alley MR, et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012;586(19):3410-3414.
12. Kircik L, Call R, Tschen E, et al. Maximal use systemic exposure (MUSE) study evaluating AN2728 topical ointment, 2%, a boron-based small molecule for the treatment of mild-to-moderate atopic dermatitis in children 2 to 17 years of age [poster]. Presented at: Copenhagen, Denmark, Annual Meeting of the European Society for Dermatological Research, September 10-13, 2014.
13. Stein-Gold L, Spelman L, Spellman MC, Hughes M, Zane LT. Safety and efficacy of AN2728 topical ointment, 2% and 0.5%, in a phase 2 dose-ranging study of adolescents with mild-to-moderate atopic dermatitis [poster]. Presented at: Kohala Coast, HI, Winter Clinical Dermatology Conference, January 17-22, 2014.
14. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107(1):51-56.
15. Volf EM, Au SC, Dumont N, Scheinman P, Gottlieb AB. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11(3):341-346.
16. Higgs G. Is PDE4 too difficult a drug target? Curr Opin Investig Drugs. 2010;11(5):495-498.